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ABSTRACT
Chlamydia trachomatis is the most common bacterial agent of sexually transmitted
infections worldwide and a common co-infection in AIDS patients. Chlamydial genital tract
infections are often asymptomatic; therefore many infections go untreated and result in
complications like chronic inflammation, ectopic pregnancy, and pelvic inflammatory disease.
Chlamydia share a unique developmental cycle and under stress, can enter a state known as
persistence, in which the bacteria are noninfectious but still viable. Removal of the stressor
allows the chlamydiae to re-enter and complete the developmental cycle. Exposure to low-dose
quinolones can cause the chlamydiae to enter persistence and halt the developmental cycle.
Notably, 1 in 20 people living with HIV/AIDS also suffers from chlamydial infections. Since the
anti-HIV drug Elvitegravir (EVG) is a quinolone derivative, we hypothesized that EVG exposure
would inhibit chlamydial development. To ascertain whether EVG affects chlamydial
development, HeLa cells were infected with C. trachomatis or C. muridarum and then either
mock treated or treated with EVG. The percent infectivity and production of infectious progeny
were determined by immunofluorescence assay and chlamydial titer assay, respectively.
Transmission electron microscopy (TEM) was used to examine chlamydial morphology and
determine whether EVG caused Chlamydia to become persistent. Though percent infectivity and
chlamydial morphology were similar between treated and untreated Chlamydia-infected cells,
the production of infectious progeny was significantly decreased in EVG-exposed Chlamydiainfected cells. These data indicate that EVG is not a persistence-inducer, but does inhibit
chlamydial development in vitro. In other studies, we tested chlamydial polymorphic membrane
protein (PMP) expression in chlamydia/HSV co-infected cells by immunofluorescence staining.
Since penicillin-induced persistence decreases the expression of some chlamydial PMPs, we
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hypothesized that expression of PMP-A and PMP-B would be decreased by HSV-induced
persistence. The results indicated that there was no significant difference in expression of PMPA or PMP-B in co-infected versus C. trachomatis singly-infected cells. These data suggest that
PMP expression is not a good indicator of chlamydial persistence when induced by HSV.

INTRODUCTION
Chlamydia trachomatis is the most common bacterial agent for sexually transmitted
disease worldwide, causing approximately 2.86 million new infections annually in the United
States alone (CDC, 2014). This number is likely an underestimate since chlamydia is largely a
“silent”, or asymptomatic, infection. Chlamydia can manifest itself in inflammatory conditions
such as urethritis or cervicitis. However, its tendency to display no visible symptoms often leads
to untreated infections which can cause complications such as pelvic inflammatory disease,
ectopic pregnancy, and infertility (Engleberg et al., 2013). Although chlamydia is primarily
transmitted through sexual contact, it can be spread from an infected pregnant woman to her
child during childbirth, since the newborn can come into contact with the pathogen upon delivery
(CDC, 2014). Infants infected with chlamydia can develop conjunctivitis or pneumonia, and
chlamydia can also cause some adults to develop a rare complication known as reactive arthritis
(Miller, 2006). As the causative agent of trachoma, the most common form of preventable visual
impairment worldwide, C. trachomatis can also be spread through direct contact with poor
hygiene conditions or flies (Mishori et al., 2012). Chronic chlamydial infections can lead to the
buildup of dead epithelial cells from the continued inflammatory and healing responses of the
host. This accumulation of necrotic cells can result in irreversible scarring in locations such as
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the female genital tract or the eyelid, contributing to infertility and trachoma, respectively
(Engleberg et al., 2013).
The genus Chlamydia contains nine species, all of which are obligate intracellular
pathogens. Chlamydial organisms must be inside living host cells to replicate. Chlamydiae can
infect a variety of hosts, ranging from humans to amoebae (Schoborg, 2011). C. trachomatis, the
human strain of chlamydial pathogens, targets epithelial cells and can be found in the mucosal
membranes of the genital tract, urinary tract, eyes, or lungs (Mishori et al., 2012). C. trachomatis
is sensitive to macrolides, tetracyclines, and fluoroquinolones; common antibiotics used to treat
the pathogen include erythromycin, doxycycline, and azithromycin (Engleberg et al., 2013). All
chlamydia share a unique biphasic developmental cycle within host cells (Figure 1). After the
epithelial host cell ingests the infectious but non-replicative elementary bodies (EB) of the
pathogen, the vacuoles containing EB within the cell fuse to form a chlamydial inclusion. Within
the inclusion, the EB differentiate into non-infectious but replicative reticulate bodies (RB). The
RB use host cell metabolites for growth and replicate through binary fission. After several
replication cycles, the RB transform back into infectious EB, which are then released by host cell
lysis or inclusion extrusion to infect more cells (Schoborg, 2011).
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Figure 1. The chlamydial developmental cycle. Infectious elementary bodies (EB) attach to
and are endocytosed by host epithelial cells to form a chlamydial inclusion. The EB within the
inclusion transform into reticulate bodies (RB), the noninfectious but replicating form of the
bacteria. After several rounds of replication, the RB transform back into EB that are then
released by host cell lysis to infect other cells. If stressors such as IFN- or β-lactam antibiotics
are introduced to chlamydia-infected cells, the chlamydia will enter a state known as persistence,
in which the bacteria are noninfectious but still viable. Persistence is characterized by the
enlargement of RB into aberrant bodies (AB) which no longer have the ability to replicate and
transform into infectious EB. Removal of such stressors allows the re-entry of the bacteria into
the normal infectious cycle (Schoborg, 2011).
When chlamydia-infected host cells are exposed to a stress such as nutrient deprivation or
certain antibiotics, the chlamydia bacteria enter a state known as persistence. Persistence is
characterized by the enlargement of RB in the inclusion and also the inhibition of their
replication and differentiation into EB (Hogan et al., 2004). In persistence, the bacteria are noninfectious but still viable. It has been shown that persistent chlamydia can re-enter the normal
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developmental cycle when stressors such as IFN- or β-lactam antibiotics are removed from
infected cells (Beatty et al., 1995; Kintner et al., 2014). Because chlamydia commonly cause
recurrent infection, some researchers have suspected a link between recurrence and persistence.
Substantial data exists from in vitro studies into this link. Experiments conducted by Dean and
Powers (2001) have shown that persistent chlamydia can alter host cell processes by resisting
apoptosis, or programmed cell death. Persistent forms of chlamydia have also been linked to proinflammatory responses and serving as reservoirs for new infections, both of which contribute to
chronic disease (Reveneau et al., 2005). Evidence also exists of a possible connection between
persistence and the development of chlamydial resistance to antibiotic treatments such as
azithromycin in cell culture (Dean, 2009).
Fewer in vivo studies into chlamydial persistence exist due to the difficulties of obtaining
live and controllable organismal models. Studies conducted by Nanagara et al. (1995) are one of
few which support the contribution of persistent chlamydia to disease chronicity in vivo, since
tissue samples from patients with chlamydia-associated arthritis were found to contain
characteristically persistent chlamydia. Recent developments by the Department of Biomedical
Sciences at the Quillen College of Medicine have led to the successful development of the first
tractable, or easily controllable, animal model of chlamydial persistence. The breakthrough
murine model has facilitated the in vivo discovery of persistent chlamydia in infected host mice
stressed by amoxicillin, the most commonly prescribed antibiotic for bacterial infections in the
United States and also the treatment of choice for pregnant women infected with chlamydia
(Campbell et al., 2012). Recent studies with this animal model have also found that persistent
chlamydiae in vivo are more resistant to azithromycin, supporting the similar results obtained in
vitro (Phillips-Campbell et al., 2014; Dean, 2009).
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Along with the biphasic developmental cycle, all chlamydial species share a unique
family of genes encoding for polymorphic membrane proteins (PMPs). C. trachomatis expresses
nine PMPs on the surface of its elementary bodies, designated PMP-A to PMP-I (Taylor, 2011).
Although the role of PMPs in chlamydial pathogenesis is not fully understood, studies suggest
that the proteins do play some role in virulence. Structural protein analysis reveals that each PMP
subtype of C. trachomatis contains several GGAI amino acid motifs, which are associated with
the adhesion of other organisms to host cells, and patients infected with C. trachomatis are
known to produce antibodies for all PMPs (Gomes et al., 2006). Variance in PMP antibody
profiles among patients infected with C. trachomatis suggests that the proteins are part of a
mechanism of antigenic variation for the bacteria to evade the immune system, adjusting to
different immunological pressures within infected hosts (Carrasco et al., 2011). In a study
conducted among women with pelvic inflammatory disease, Taylor et al. (2011) found that those
who expressed antibodies for PMP-A were less likely to achieve pregnancy or a live birth and
those who expressed antibodies for PMP-I were more likely to have upper genital tract
infections. Data from this study also revealed an increase of inflammatory markers in women
with PMP-A antibodies, suggesting that PMP-A could serve as a potential biomarker for the
increased risk of secondary sequelae from C. trachomatis infection (Taylor et al., 2011).
The expression of PMPs in relation to persistence has also been explored. A study by
Carrasco et al. (2011) discovered that the transcription of some PMPs, such as PMP-B, is
downregulated in C. trachomatis-infected cells under conditions of penicillin-induced
persistence. Since in vitro studies by Deka et al. (2006) have found that chlamydial persistence
can also be induced by co-infection of host cells with herpes simplex virus type-2 (HSV-2), we
hypothesized that expression of certain PMPs, in this case PMP-A and PMP-B, would be
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decreased under conditions of HSV-induced persistence. The question was explored to further
determine whether PMPs could be used as biomarkers of chlamydial persistence in vivo.
In addition to being one of the most common sexually transmitted infections in the world,
chlamydia is a common co-infection in human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) patients. A systematic review of 37 clinical and
epidemiological studies of STI co-infections in HIV/AIDs patients across the world reports that 1
in 20 people living with HIV/AIDS also have chlamydia (Kalichman et al., 2011). One widely
used class of anti-HIV drugs is comprised of integrase strand transfer inhibitors (INSTIs).
INSTIs target the viral enzyme integrase, which is responsible for incorporating the retroviral
DNA of HIV into the host genome. Some integrase inhibitors in clinical use today are
raltegravir, dolutegravir, and elvitegravir (EVG), the drug of interest to our studies (Quashie,
2012). EVG, approved for use by the U.S. Food and Drug Administration in 2012, is a
component of the pharmaceutical drug
Stribild. Its mechanism of action
consists of inhibiting integrase by
preventing HIV-1 DNA strand transfer
and integration (Lee et al., 2012).
Studies have shown that EVG has
broad antiretroviral activity, effectively
inhibiting HIV replication, as well as
that of simian immunodeficiency virus

Figure 2. The structure of Elvitegravir (Shimura, 2008).

and murine leukemia virus (Shimura et al., 2008). Most INSTIs achieve their selectivity through
the inclusion of a diketo acid moiety (DKA) in their structure, but EVG’s structure (Figure 2)
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actually contains a monoketo acid, a modified DKA, which maintains a high specificity for the
strand transfer reaction (Quashie, 2012).
EVG is also a quinolone derivative. Although chlamydial infections can often be
effectively treated by fluoroquinolones such as ofloxacin and levofloxacin, research shows that
quinolones may also have a role in persistence. Subinhibitory or low dose concentrations of
fluoroquinolones can produce fluoroquinolone-resistant mutants of C. trachomatis (DessusBabus et al., 1998). Testing conducted by Somani et al. (2000) on clinical isolates of C.
trachomatis-infected patients who experienced treatment failure found that the chlamydiae
exhibited multidrug resistance to common treatments such as ofloxacin. From the genotyping of
the primary isolates and separate isolates obtained from infection relapses in those patients, it
was found that recurrent disease was caused by the same resistant organisms and that many
aberrant inclusions were present among the resistant strains. One theory of the researchers
suggested that resistance may be linked to an alteration in the chlamydial life cycle resulting in
some intermediate stage (i.e. persistence) which would make the bacteria more refractive to
antimicrobial agents. Although other theories were also put forth as an explanation for the
mechanism of resistance, it is possible that exposure to certain concentrations of antimicrobial
agents such as ofloxacin induced the chlamydia to enter persistence (Somani et al., 2000). In
another study by Patton et al. (1993), C. trachomatis-infected monkey models were treated with
a quinolone analog therapy. Although chlamydial organisms were no longer recoverable in cell
culture after completion of the therapy, chlamydial DNA was consistently present post-therapy,
suggesting the presence of either dead organisms or viable organisms in an unculturable state
(i.e. persistent organisms) (Patton et al., 1993). Since exposure to low-dose quinolones is
implicated in chlamydial persistence and EVG is a quinolone derivative, we hypothesized that
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EVG would inhibit chlamydial development. The question is relevant, considering the
prevalence of chlamydial co-infections in HIV/AIDS patients and the fact that these patients
must be on anti-HIV drugs for life. If EVG inhibits chlamydial replication, HIV patients on EVG
would be expected to be more resistant to chlamydial infection.

MATERIALS AND METHODS
Chlamydia, HSV-2 and host cells:
HeLa cells, a human cervical adenocarcinoma epithelial cell line (ATCC CCL2) were
used for both studies. A human urogenital isolate of C. trachomatis E/UW-5/CX was originally
obtained from S.P. Wang and C. Kuo (University of Washington, Seattle, WA). C. muridarum
Weiss strain was obtained from Dr. Kyle Ramsey. The same standardized inoculum of C.
trachomatis serovar E or C. muridarum elementary bodies, propagated in Hec1B cells (human
endometrial cell line ATCC#HTTB-113), was used for all experiments (Wyrick et al., 1996).
HSV-2 strain 333 stocks were obtained from Mary K. Howett. Viral stocks were prepared in
monolayers of Vero cells (African green monkey kidney cells ATCC No. CCL-81) using
standard techniques (Duff and Rapp, 1971).
EVG studies:
Cell culture. HeLa cells were plated and infected with C. trachomatis serovar E or C.
muridarum Weiss and exposed to either Elvitegravir (Selleckchem.com #S2001), amoxicillin, or
tetracycline at physiologically relevant concentrations:
Drug

Class

Amoxicillin (AMX) Penicillin

Serum (1X) concentration Diluent
11 g/mL

Water (ddH2O)
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Tetracycline (TET)

Tetracycline 4.3 g/mL

Elvitegravir (EVG)

Quinolone

1.7 g/mL

Water (ddH2O)
Dimethyl sulfoxide
(DMSO)

Table 1. Physiologically relevant drug concentrations.
Replicate cultures were either exposed to medium + diluent (DMSO or water, as appropriate),
medium + amoxicillin, medium + tetracycline, or medium + EVG (1X [1.7 g/mL]
concentration) and incubated at 35°C. At 48 hours post infection, samples were collected for titer
assay, immunofluorescence staining, and transmission electron microscopy.
Determining EVG concentration. The physiologically relevant concentration of EVG
was set at 1.7 g/mL (Ramanathan, 2008; “Stribild,” 2013). That is the maximum concentration
of EVG that can be found in human serum when ingested in the form of the trademark drug
Stribild.
Immunofluorescence assay (IFA) and percent infectivity. At 48 hours post infection,
cell monolayers were fixed and permeabilized with 1 mL cold methanol for 20 minutes. Glass
coverslips for C. trachomatis and C. muridarum were stained with anti-chlamydial MOMP stain
and LPS stain (Bio-Rad #30702 and #30701), respectively. All coverslips were counterstained
with DAPI and mounted on glass slides. The number of inclusions and host cell nuclei in 10
fields/coverslip was determined at 630x magnification under oil immersion using an Axiovert
S100 (Zeiss) microscope and Axiovert imaging software. Percent infectivity was calculated as
the number of inclusions divided by the number of host cell nuclei per field on the coverslips.
The data were analyzed statistically using a two-tailed t test with p<0.05 considered significant.
Infectious titer assay. Chlamydial titrations were conducted as previously described
(Deka et al., 2006) using LPS and MOMP stains (Bio-Rad) to identify chlamydial inclusions
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formed from subpassaged EB. The number of inclusion-forming units (IFU) in the undiluted
inoculum was derived from triplicate counts and expressed as IFU/mL (Hall et al., 2014).
Transmission electron microscopy (TEM) processing. Cultured cells were scraped into
gluteraldehyde/paraformaldehyde TEM fixative and incubated at 4°C for 1 hour before further
processing. All samples were washed with cacodylate buffer and then incubated with 1%
osmium tetroxide in cacodylate buffer for 1 hour at room temperature. Samples were washed
again with cacodylate buffer and dehydrated with gradually increasing concentrations of ethanol
before infiltration with Eponate 812 (Polysciences, Inc., Warrington, PA). Samples were finally
embedded in fresh Epon, thin sectioned, and visualized using a Tecnai Philips transmission
electron microscope at 80kV. All electron micrographs were taken at 12700x magnification.

PMP studies:
Cell culture. HeLa cells were divided into four groups for mock infection, chlamydial
infection, HSV-2 infection, and C. trachomatis/HSV-2 double infection. Host cells were
incubated with a dilution of crude EB stock calculated to infect greater than 80% of the cells.
After one hour of adsorption, monolayers were refed with Minimal Essential Medium (MEM;
Invitrogen #11095-098) and incubated at 35°C for 24 hours. Cultures were then infected with
HSV-2 at a multiplicity of infection (MOI) of 10 plaque forming units (PFU) per cell. Mockinfected HeLa cells were treated similarly, except they were exposed to either 2SPG (0.2M
sucrose, 6mM NaH2PO4, 15mM Na2HPO4, 5mM L-glutamine, pH 7.2; mock C. trachomatis
infection) or growth medium (mock viral infection). After HSV adsorption, monolayers were
refed with MEM and incubated at 35°C for 20 hours.
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Flourescent staining and microscopy. The same staining procedures were used for
PMP-A and PMP-B. Fluorescence analysis samples were prepared as described previously using
formaldehyde fixation (Deka et al., 2006). Fixed cells were stained using the Carrasco et al.
(2011) protocol. Anti-PMP primary antibodies were a kind gift from Dr. Patrick Bavoil (Tan,
2009).
To make a 1:25 initial dilution of anti-PMP primary antibody (guinea pig), 4 µL of antiPMP primary antibody was added into a tube containing 96 µL of PBS (phosphate buffered
saline) washing buffer. Fixed HeLa cells were washed 3 times in 1X PBS washing buffer, and
then 100 µl of diluted primary antibody was added into each well of HeLa cells. The plate was
then placed on a gyrator shaker at a speed of 3.5 for 30 minutes at room temperature to preadsorb the antisera. This process removes antibodies that cross-react to HeLa cell antigens (to
reduce staining background), while anti-chlamydia PMP antibodies remain. The resulting preabsorbed antibody was then used as the primary antibody for all subsequent fluorescence
staining of chlamydia-infected cells. The secondary antibody (Alexa Fluor 488 goat anti-guinea
pig (IgG)) (Invitrogen #A-11073) was diluted to a concentration of 1:500 with PBS washing
buffer and DAPI solution.
For fluorescence staining, 10 L drops of dilute primary antibody were pipetted onto
parafilm. Sample coverslips were washed with PBS washing solution and inverted onto the
primary antibody drops, cell monolayer down. Coverslips were incubated at 37°C for 1 hour and
then washed with PBS washing buffer before secondary staining. Ten L drops of secondary
antibody were pipetted onto parafilm, and coverslips were inverted onto the drops and incubated
at 37°C for 30 minutes. Coverslips were then washed with PBS washing buffer again before
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being mounted (Fluoromount Fisher #OB100-01) on glass slides and stored in a dark drawer to
dry.
Using an Axiovert S100 (Zeiss) microscope and Axiovert imaging software, the intensity
of 50 inclusions from singly-infected cells and 50 chlamydial inclusions from co-infected cells
were quantified and compared for each one of three replicates. Inclusion intensity measurements
were divided by inclusion area measurements, and the resulting measurements for all three
replicates of each sample were averaged to compare the expression of the PMP of interest in the
chlamydial-infected cells versus the chlamydial/HSV-2 co-infected cells. Statistical analyses of
the data were conducted using a two-tailed t test with p<0.05 considered significant.

RESULTS
EVG studies:

Several EVG studies were conducted. The following are representative data for the
effects of EVG found on both the development of C. trachomatis and C. muridarum. The results
encapsulate the percent infectivity obtained from IFA staining, production of infectious progeny
from chlamydial titer assay, and chlamydial inclusion morphology from TEM analysis. Percent
infectivity is equal to the number of chlamydial inclusions divided by the number of host cells
counted per microscopic field on sample coverslips. Inclusion and cell counts were conducted on
individual IFA images (Figures 4 and 6, for example) and average percent infectivity values
were then calculated (Figures 3 and 5). Percent infectivity was used to determine if any great
differences in infectivity, which could have affected experimental results, existed among the
samples.
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Figure 3. EVG Exposure Does Not Inhibit C. trachomatis Inclusion Formation. Percent
infectivity (number of chlamydial inclusions divided by number of host cell nuclei) for three
replicates (n=3) of C. trachomatis serovar E-infected samples stained using
immunofluorescence assay (IFA) staining. An asterisk (*) indicates a statistically significant
difference found after conducting a two-tailed t test using p<0.05 for significance. Mock,
AMX, and TET samples were compared to CtE –DMSO positive control samples (data not
shown). EVG samples were compared to the CtE +DMSO positive control samples. These
data were obtained from study EVG.02.

Figure 4. IFA-stained cells at magnification 630x under oil immersion: A. mock B. CtE
+amoxicillin (AMX) C. CtE +DMSO D. CtE +EVG 1X concentration (1.7 g/mL). Host cell
nuclei are stained blue by DAPI stain and chlamydial inclusions are stained green by MOMP
stain.
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Figure 5. EVG Exposure Does Not Inhibit C. muridarum Inclusion Formation. Percent
infectivity (number of chlamydial inclusions divided by number of host cell nuclei) for three
replicates (n=3) of C. muridarum-infected samples stained using immunofluorescence assay
(IFA) staining. An asterisk (*) indicates a statistically significant difference found after
conducting a two-tailed t test using p<0.05 for significance. Mock, AMX, and TET samples
were compared to Cm –DMSO positive control samples (data not shown). EVG samples
were compared to the Cm +DMSO positive control samples. These data were obtained from
study EVG.07.

Figure 6. IFA-stained cells at magnification 630x under oil immersion: A. Cm +tetracycline
(TET) B. Cm +AMX C. Cm +DMSO D. Cm +EVG 1X concentration (1.7 g/mL). Host cell
nuclei are stained blue by DAPI stain and chlamydial inclusions are stained green by LPS stain.

17
As expected, mock infected monolayers for both C. trachomatis (Figure 3) and C.
muridarum (Figure 5) did not contain inclusions since those samples were not infected with
chlamydia. Tetracycline-exposed C. trachomatis (Figure 3) and C. muridarum (Figure 5) did
not display any inclusions, as was also expected, since tetracycline effectively kills chlamydia
and prevents inclusions from developing. In contrast, amoxicillin-exposed samples for each
species did contain inclusions. Amoxicillin served as a control for chlamydial persistence, so the
drug did not inhibit the formation of inclusions. Diluent control cultures of chlamydia containing
ddH2O (the diluent used for TET and AMX) were also performed (data not shown). Chlamydial
samples exposed to DMSO were used as a comparative reference for EVG samples since the
EVG samples contained DMSO as the diluent for the drug. Statistical analysis for EVG-exposed
versus unexposed chlamydia for both species showed that there was not a significant decrease in
the formation of inclusions (Figures 3 and 5). It was thus determined that EVG did not
significantly alter the percent infectivity and therefore did not pose a significant problem for
interpreting other experimental results obtained for either EVG-exposed C. trachomatis or C.
muridarum.
IFA images reveal a first look into inclusion morphology for the treated samples. Mock
samples (Figure 4A) only exhibit blue host cell nuclei since no chlamydia are present to bind the
FITC-labeled anti-LPS antibody (which fluoresces green). Residues of killed chlamydial
inclusions are labeled by anti-LPS in tetracycline-exposed chlamydial cultures (Figure 6A).
Amoxicillin-exposed chlamydia (Figures 4B, 6B) appeared persistent. Large, aberrant bodies
can be seen within the insets of the inclusions. Chlamydia exposed to DMSO (Figures 4C, 6C)
and EVG (Figures 4D, 6D) displayed very similar inclusion morphologies, which were clearly
distinct from the amoxicillin-exposed chlamydia.
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Figure 7. EVG Exposure Reduces Production of Infectious C. trachomatis Elementary
Bodies. Titer assay results showing the number of infectious, recoverable EB counted from C.
trachomatis serovar E-infected samples. An asterisk (*) indicates a statistically significant
difference compared to the CtE +DMSO positive control samples found after conducting a twotailed t test using p<0.05 for significance.

Figure 8. EVG Exposure Reduces Production of Infectious C. muridarum Elementary
Bodies. Titer assay results showing the number of infectious, recoverable EB counted from C.
muridarum-infected samples. An asterisk (*) indicates a statistically significant difference
compared to the Cm +DMSO positive control samples found after conducting a two-tailed t test
using p<0.05 for significance.
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Titer results (Figures 7 and 8) for both C. trachomatis and C. muridarum showed that
mock-, AMX-, and TET-exposed samples did not produce infectious EB, as expected. Although
chlamydia can form inclusions when AMX exposed, the organisms are persistent (noninfectious)
and thus not producing infectious EB. Titer data revealed a significant decrease in the production
of viable infectious progeny from chlamydia exposed to EVG at the physiologically relevant
(1X) concentration. Compared to the DMSO-exposed chlamydia, there was a much lower
number of recoverable EB found from the EVG-exposed chlamydia. These results were
consistently reproduced in several experimental replications and suggest that exposure to EVG
causes a reduction in the production of infectious EB.
Transmission electron micrographs (TEMs) (Figure 9 below) provided an up-close look
into individual inclusions. As the figure shows, the morphology of C. trachomatis and C.
muridarum inclusions appears very similar among samples exposed to DMSO and samples
exposed to EVG. Both EB, indicated by yellow arrows, and RB, indicated by white arrows, are
scattered throughout. This confirms the results of the IFA images, which also appeared to show
morphologically similar inclusions between DMSO- and EVG-exposed samples. TEMs of
characteristically persistent inclusions (images not shown) display very large, aberrant bodies.
The aberrant bodies are few in number since persistent chlamydia cease replicating, and there is
also an absence of the small, dark infectious EB since persistent chlamydia are also
noninfectious.
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Figure 9. EVG Exposure Does Not Significantly Alter C. trachomatis or C. muridarum
Morphology. Transmission electron micrographs at magnification 12700x: A. CtE +DMSO
B. CtE +EVG 1X concentration (1.7 g/mL) C. Cm +DMSO D. Cm + EVG 1X concentration.
White arrows indicate RB and yellow arrows indicate EB within the chlamydial inclusions.
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PMP studies:
The following are results from our studies of the expression of both PMP-B and PMP-A
under conditions of HSV-induced persistence. Chlamydial PMP expression was measured by the
amount of inclusion intensity from fluorescence staining divided by inclusion area.
0.086
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Figure 10. Co-infection Does Not Significantly Alter C. trachomatis PMP-B Accumulation.
Average inclusion intensity/area measurements for three replicates (n=3) of PMP-B stained
CtE/HSV co-infected versus CtE-infected cells. There was no significant difference between
inclusion intensity staining with PMP-B antibody between co-infected and singly-infected
samples (p>0.05).

22

Figure 11. HeLa cells stained with PMP-B antibody at 400x magnification. A. mock B. HSVinfected C. CtE/HSV co-infected D. CtE-infected.
6
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Figure 12. Co-infection Does Not Significantly Alter C. trachomatis PMP-A Accumulation.
Average inclusion intensity/area measurements for three replicates (n=3) of PMP-A stained
CtE/HSV co-infected versus CtE-infected cells. There was no significant difference between
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inclusion intensity staining with PMP-A antibody between co-infected and singly-infected
samples (p>0.05).

Figure 13. HeLa cells stained with PMP-A antibody at 400x magnification. A. mock B. HSVinfected C. CtE/HSV co-infected D. CtE-infected.
Results (Figures 10 and 11) revealed that there is no significant difference in expression
of either PMP-B or PMP-A staining intensity between chlamydia-infected and chlamydia/HSV-2
co-infected cells. Representative images of PMP-B and PMP-A expression can be viewed in
Figure 11 and Figure 13, respectively.

DISCUSSION
Contrary to our initial hypothesis, the data from our PMP studies show that there was no
significant difference in expression of PMP-A or PMP-B between unstressed chlamydia and
chlamydia stressed by HSV-2. This suggests that neither PMP-B nor PMP-A play a special role
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in chlamydial persistence when induced by HSV-2, leading to the conclusion that neither PMP
would serve as a good biomarker of persistence when induced by HSV-2. Since Carrasco et al.
(2011) did find some decreased levels of PMP expression among persistent chlamydia induced
by penicillin, it seems that whether or not PMP expression changes during persistence may vary
according to the type of stimulus that is used to induce persistence. Experimentation involving
different inducers of persistence, such as IFN- or other β-lactams like amoxicillin, would be
helpful in further exploring the question.
The results from EVG studies also lead to further questions. It can be directly observed
from both IFA and TEM visuals that the appearance of EVG treated and untreated chlamydial
inclusions is very similar. Exhibiting inclusions with EB and RB similar to the DMSO-exposed
chlamydia, EVG exposure appears to not alter normal inclusion formation. It is clear by
comparison to references of persistence such as the amoxicillin-exposed chlamydia that EVG is
not inducing chlamydia into persistence. This would point to the conclusion that EVG has no
effect on chlamydial development, but the results of infectious titer assays indicate otherwise.
Since titer results revealed that EVG exposure significantly reduces the production of infectious
EB in both C. trachomatis and C. muridarum, it appears that EVG does inhibit chlamydial
development in vitro at physiologically relevant concentrations. Since this inhibition of the
production of infectious progeny does not seem to be linked to persistence, it appears that
another mechanism may be at work.
Although the mechanism of this inhibition of chlamydial development is currently
unknown, there are several possibilities. Although TEMs indicate that EB are still present within
chlamydia exposed to EVG, titer assays indicate that the EB are significantly less infectious.
EVG could be reducing the infectious nature of EB after they are produced. It is possible, for
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example, that the drug could be interacting with and partially inactivating EB surface proteins
that are required for the EB to infect new cells. It is also possible that EVG could be delaying the
release of EB from inclusions or that its activity could differ depending on the timing of the
drug’s addition to chlamydia infected cells. Further experimentation involving variations in
timing of the drug’s addition to infectious samples could shed more light on its activity.
Preliminary studies involving mice have been conducted in order to ascertain the effects
of EVG in vivo. A group of 4 mice were administered with Stribild, the pharmaceutical drug
form of EVG, to observe effects on chlamydial shedding. Compared to untreated mice, the mice
administered with Stribild exhibited a shorter duration of chlamydial shedding by about 6 days.
Stribild treated mice also seemed to show less gross pathology as well. Although an interesting
finding, these results are interpreted with caution due to the very preliminary nature of the study.
Only a small number of mice were used, so the reliability of the data is questionable until the
experiment can be reproduced on a greater scale.
Although not serving as a persistence-inducer, EVG clearly has some inhibitory effect on
the development of chlamydia in vitro. Further experiments involving animal models or other
anti-HIV drugs similar to EVG may be used in the future to understand more about the
mechanism at work.
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